Microbicide delivery: Formulation technologies and strategies

Current Opinion in HIV and AIDS

Volumn 3, Issue 5, 2008, Pages 558-566

  Romano, Joseph ^a   Malcolm, R Karl ^b   Garg, Sanjay ^c   Rohan, Lisa C ^d   Kaptur, Paulina E ^a  

^a INTERNATIONAL PARTNERSHIP FOR MICROBICIDES   (United States)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^c UNIVERSITY OF AUCKLAND   (New Zealand)

^d UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Acceptability; Formulation; HIV; Microbicide; Vaginal dosing

Indexed keywords

17BETA ESTRADIOL 3 ACETATE; CARBOMER; CARBOPOL 974P; CARRAGEENAN; CELLACEFATE; CELLULOSE ACETATE 1,2 BENZENE DICARBOXYLATE; CELLULOSE SULFATE; DAPIVIRINE; DODECYL SULFATE SODIUM; ESTRADIOL; ESTRADIOL DERIVATIVE; ETHINYLESTRADIOL PLUS ETONOGESTREL; EXCIPIENT; FEMRING; HERBACEOUS AGENT; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HYDROXYETHYLCELLULOSE; MICROBICIDE; N [4 CHLORO 3 (3 METHYL 2 BUTENYLOXY)PHENYL] 2 METHYL 3 FURANCARBOTHIOAMIDE; NONOXINOL 9; PC 815; POLYMER; POLYSTYRENESULFONATE SODIUM; PRANEEM; PRO 2000; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAVVY; SURFACE ACTIVE ENVELOPE SOLUBILIZING AGENT; TENOFOVIR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIVAGEL; ZIDOVUDINE;

CLINICAL TRIAL; CONDOM; CONTRACEPTION; CREAM; DISSOLUTION; DRUG ADSORPTION; DRUG COST; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FORMULATION; DRUG IMPURITY; DRUG PENETRATION; DRUG POTENCY; DRUG RELEASE; DRUG SAFETY; DRUG SOLUBILITY; ESTROGEN THERAPY; EXCIPIENT COMPATIBILITY; FILM; FIRST PASS EFFECT; FOAM; GEL; HEMORRHOID; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LACTOBACILLUS; LARGE SCALE PRODUCTION; LIQUID; LOTION; OINTMENT; OSMOLALITY; OSMOLARITY; PATIENT COMPLIANCE; PH; PRIORITY JOURNAL; PROCTITIS; REVIEW; SEXUAL BEHAVIOR; SEXUAL TRANSMISSION; SUPPOSITORY; SUSPENSION; SUSTAINED DRUG RELEASE; TABLET; TECHNOLOGY; VAGINA RING; VAGINAL OVULE; VISCOSITY; WATER CONTENT;

EID: 65549157434     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e328305b96e     Document Type: Review

References (129)

1. Scholand SJ, DeSimone JA, Pomerantz RJ. Anti-HIV-1 microbicides: 'chemical condoms' designed to limit the scourge of the HIV-1 pandemic. Curr Pharm Des 2005; 11:3747-3756.
2. D'Cruz OJ, Uckun FM. Dawn of nonnucleoside inhibitor-based anti-HIV microbicides. J Antimicrob Chemother 2006; 57:411-423.
3. Lederman MM, Offord RE, Hartley O. Microbicides and other topical strategies to prevent vaginal transmission of HIV. Nat Rev Immunol 2006; 6: 371-382.
4. Raymond EG, Chen PL, Condon S, et al. Acceptability of five nonoxynol-9 spermicides. Contraception 2005; 71:438-442.
5. Lete I, Doval JL, Perez-Campos E, et al. Factors affecting women's selection of a combined hormonal contraceptive method: The TEAM-06 Spanish cross-sectional study. Contraception 2007; 76:77-83. This article compares acceptability rates for the contraceptive IVR, pill, and skin patch.
6. Creinin MD, Meyn LA, Borgatta L, et al. Multicenter comparison of the contraceptive ring and patch: a randomized controlled trial. Obstet Gynecol 2008; 111 (2 Pt 1):267-277. This article compares acceptability rates for pill users randomized to the IVR or skin patch.
7. Merki-Feld GS, Hund M. Clinical experience with NuvaRing® in daily practice in Switzerland: Cycle control and acceptability among women of all reproductive ages. Eur J Contracept Reprod Heath Care 2007; 12:240-247. This article describes acceptability of the IVR, especially as related to insertion and removal.
8. Ahrendt HJ, Nisand I, Bastianelli C, et al. Efficacy, acceptability and tolerability of the combined contraceptive ring, NuvaRing, compared with an oral contraceptive containing 30 microg of ethinyl estradiol and 3mg of drospirenone. Contraception 2006; 74:451-457.
9. Schafer JE, Osborne LM, Davis AR, Westhoff C. Acceptability and satisfaction using Quick Start with the contraceptive vaginal ring versus an oral contraceptive. Contraception 2006; 73:488-492.
10. Ballagh SA, Brache V, Mauck C, et al. A phase I study of the functional performance, safety and acceptability of the BufferGel Duet. Contraception 2008; 77:130-137. This article describes the use and acceptability of a new microbicide product with an applicator that serves as a mechanical barrier.
11. Balzarini J, Van Damme L. Microbicide drug candidates to prevent HIV infection. Lancet 2007; 369:787-797. This review article describes different categories of microbicide drugs, their mechanisms of action and status of development. Progress in phase III trials is reported.
12. Balzarini J, Van Damme L. Intravaginal and intrarectal microbicides to prevent HIV infection. CMAJ 2005; 172:461-464.
13. Olmsted SS, Khanna KV, Ng EM, et al. Low pH immobilizes and kills human leukocytes and prevents transmission of cell-associated HIV in a mouse model. BMC Infect Dis 2005; 5:79.
14. Bentley ME, Fullem AM, Tolley EE, et al. Acceptability of a microbicide among women and their partners in a 4-country phase I trial. Am J Publ Health 2004; 94:1159-1164.
15. Roth S, Monsour M, Dowland A, et al. Effect of Topical microbicides on infectious human immunodeficiency virus type 1 binding to epithelial cells. Antimicrob Agents Chemother 2007; 51:1972-1978. This paper reports on the in-vitro binding of HIV-1 to epithelial cells in the presence of microbicide gels currently in preclinical and clinical trials.
16. Lu H, Zhao Q, Wallace G, et al. Cellulose acetate 1,2-benzenedicarboxylate inhibits infection by cell-free and cell-associated primary HIV-1 isolates. AIDS Res Hum Retroviruses 2006; 22:411-418.
17. Trifonova RT, Pasicznyk JM, Fichorova RN. Biocompatibility of solid-dosage formsof antihuman immunodeficiency virus type 1 microbicideswith the human cervicovaginal mucosa modeled ex vivo. Antimicrob Agents Chemother 2006; 50:4005-4010.
18. Boadi T, Schneider E, Chung S, et al. Cellulose acetate 1,2-benzenecarboxylate protects against challenge with pathogenic X4 and R5 simian/human immunodeficiency virus. AIDS 2005; 19:1587-1594.
19. Otten RA, Adams DR, Kim CN, et al. Multiple vaginal exposures to low doses of R5 simian-human immunodeficiency virus: strategy to study HIV preclinical interventions in nonhuman primates. J Infect Dis 2005; 191:164-173.
20. Ratterree M, Gettie A, Williams V, et al. Safety and distribution of cellulose acetate 1,2-benzenedicarboyxylate (CAP), a candidate anti-HIV microbicide in rhesus macaques. AIDS 2005; 19:1595-1599.
21. Trial Shows Anti-HIV Microbicide Is Safe, but Does Not Prove It Effective. Research Advances HIV Prevention Field. http://www.popcouncil.org/ mediacenter/newsreleases/Carraguard-Findings.html. [Accessed 18 March 2008].
22. Kilmarx PH, van de Wijgert JH, Chaikummao S, et al. Safety and acceptability of the candidate microbicide Carraguard in Thai women: findings from a phase II clinical trial. J Acquir Immune Defic Syndr 2006; 43:327-334.
23. Braunstein S. Acceptability of Carraguard1 among HIV-infected women and men in a safety trial in South Africa [abstract]. In: Microbicides 2004; 28-31 March 2004; London. Washington, DC: Global Campaign for Microbicides; 2004. Abstract # 02463-2.
24. Elias CJ, Coggins C, Alvarez F, et al. Colposcopic evaluation of a vaginal gel formulation of iota-carrageenan. Contraception 1997; 56:387-389.
25. El-Sadr WM, Mayer KH, Maslankowski L, et al. Safety and acceptability of Cellulose sulfate as a vaginal microbicide in HIV-infected women. AIDS 2006; 20:1109-1116.
26. Malonza IM, Mirembe F, Nakabiito C, et al. Expanded phase 1 safety and acceptability study of 6% cellulose sulfate vaginal gel. AIDS 2005; 19:2157-2163.
27. Scordi-Bello IA, Mosoian A, He C, et al. Candidate sulfonated and sulfated topical microbicides: comparison of antihuman immunodeficiency virus activities and mechanisms of action. Antimicrob Agents Chemother 2005; 49:3607-3615.
28. Mauck C, Weiner DH, Ballagh S, et al. Single and multiple exposure tolerance study of cellulose sulfate gel: a phase I safety and colposcopy study. Contraception 2001; 64:383-391.
29. Van Herrewege Y, Michiels J, Van Roey J, et al. In vitro evaluation of nonnucleoside reverse transcriptase inhibitors UC-781 and TMC120-R147681 as human immunodeficiency virus microbicides. Antimicrob Agents Chemother 2004; 48:337-339.
30. Di Fabio S, Van Roey J, Giannini G, et al. Inhibition of vaginal transmission of HIV-1 in hu-SCID mice by the nonnucleoside reverse transcriptase inhibitor TMC120 in a gel formulation. AIDS 2003; 17:1597-1604.
31. Alliance for Microbicide Development. Microbicide candidates in clinical development. Microbicide Quarterly 2007; 5: 4. http://www.microbicide. org/microbicideinfo/reference/TMQ.Apr-Jun2007.FINAL.pdf. [Accessed 17 March 2008].
32. Trottier S, Omar RE, Désormeaux A, et al. Safety, tolerance and acceptability of the Invisible Condom and its vaginal applicator in healthy women and their male sexual partners. Contraception 2007; 76:117-125. This study established the safety and acceptability of the Invisible Condom. It is now in phase I/II clinical trials.
33. D'Cruz OJ, Uckun FM. Clinical development of microbicides for the prevention of HIV infection. Curr Pharm Des 2004; 10:315-336.
34. Nonclinical Laboratory Studies: PC-815 (Carraguard + MIV-150). http:// www.popcouncil.org/projects/MIC-PC-815NonclinLab.html. [Accessed 18 March 2008].
35. Fernandez-Romero JA, Thorn M, Turville SG, et al. Carrageenan/MIV-150 (PC-815): a combination microbicide. Sex Transm Dis 2007; 34:9-14. This paper describes the in-vitro anti-HIV effect of PC-815, a combination gel product containing Carraguard and the NNRTI MIV-150.
36. Indevus Pharmaceuticals Provides Update on PRO 2000 Program. http:// phx.corporate-ir.net/phoenix.zhtml?c=92810&p=irol-newsArticle&ID= 1108774 &highlight=. [Accessed on 18 March 2008].
37. Joglekar N, Joshi S, Kakde M, et al. Acceptability of PRO2000 vaginal gel among HIV un-infected women in Pune, India. AIDS Care 2007; 19:817-821. This paper established that PRO2000, which is now in phase III, is acceptable to Indian women.
38. Lacey CJ, Wright A, Weber JN, et al. Direct measurement of in vivo vaginal microbicide levels of PRO 2000 achieved in a human safety study. AIDS 2006; 20:1027-1030.
39. Smita J, Soma D, Beverly B, et al. Phase I safety study of 0.5% PRO 2000 vaginal gel among HIV un-infectedwomen in Pune, India. AIDSRes Ther 2006; 3:4.
40. Mayer KH, Karim SA, Kelly C, et al. Safety and tolerability of vaginal PRO 2000 gel in sexually active HIV-uninfected and abstinent HIV-infected women. AIDS 2003; 17:321-329.
41. Morrow K, Rosen R, Richter L, et al. The acceptability of an investigational vaginal microbicide, PRO 2000 gel, among women in a phase I clinical trial. J Women's Health (Larchmt) 2003; 12:655-666.
42. Feldblum PJ, Adeiga A, Bakare R, et al. SAVVY vaginal gel (C31G) for prevention of HIV infection: a randomized controlled trial in Nigeria. PLoS ONE 2008; 3:e1474. This phase III study showed that SAVVY did not reduce HIV infection.
43. Peterson L, Nanda K, Opoku BK, et al. SAVVY® (C31G) gel for prevention of HIV infection in women: a phase 3, double-blind, randomized, placebo-controlled trial in Ghana. PLoS ONE 2007; 2:e1312. This phase III study was not able to show that SAVVY use was associated with reduction of HIV incidence. Although not associated with a higher incidence of adverse events overall, it was associated with a higher incidence of reproductive adverse events.
44. Ballagh SA, Baker JM, Henry DM, et al. Safety of single daily use for one week of C31G HEC gel in women. Contraception 2002; 66:369-375.
45. Bax R, Douville K, McCormick D, et al. Microbicides: evaluating multiple formulations of C31G. Contraception 2002; 66:365-368.
46. Peterson L, Taylor D, Roddy R, et al. Tenofovir disoproxil fumerate for prevention of HIV infection in women: a phase 2, double-blind, randomized, placebo-controlled trial. PLoS Clin Trials 2007; 2:e27.
47. Mayer KH, Maslankowski LA, Gai F, et al. Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women. AIDS 2006; 20:543-551.
48. Lyseng-Williamson KA, Reynolds NA, Plosker GL. Tenofovir disoproxil fumerate: a review of its use in the management of HIV infection. Drugs 2005; 65:413-432.
49. Patton DL, Sweeney YTS, Balkus JE, et al. Preclinical safety assessments of UC781 antihuman immunodeficiency virus topical microbicide formulations. Antimicrob Agents Chemother 2007; 51:1608-1615. This article reports on the safety of UC781, an NNRTI, in macaques when administered vaginally or rectally.
50. Hossain MM, Parniak MA. In vitro mitochondrial activity of the nonnucleoside reverse transcriptase inhibitor (NNRTI)UC781 against NNRTI-resistant human immunodeficiency virus type 1. J Virol 2006; 80:4440-4446.
51. Fletcher P, Kiselyeva Y, Wallace G, et al. The nonnucleoside reverse transcriptase inhibitor UC-781 inhibits human immunodeficiency virus type 1 infection of human cervical tissue and dissemination by migratory cells. J Virol 2005; 79:1179-1186.
52. Zussman A, Lara L, Lara HH, et al. Blocking of cell-free and cell-associated HIV-1 transmission through human cervix organ culture with UC781. AIDS 2003; 17:653-661.
53. Schwartz JL, Ballagh SA, Kwok C, et al. Fourteen-day safety and acceptability study of the universal placebo gel. Contraception 2007; 75:136-141. This study established that an HEC-based gel is safe for use as a placebo gel in HIV prevention trials with microbicide candidates.
54. Tien D, Schnaare RL, Kang F, et al. In vitro and in vivo characterization of a potential universal placebo designed for use in vaginal microbicide clinical trials. AIDS Res Hum Retroviruses 2005; 21:845-853.
55. Lackman-Smith C, Osterling C, Luckenbaugh K, et al. Development of a comprehensive human immunodeficiency virus type 1 (HIV-1) screening algorithm for discovery and preclinical testing of topical microbicides. Antimicrob Agents Chemother 2008; 52:1768-1781.
56. Rupp R, Rosenthal SL, Stanberry LR. VivaGel (SPL7013 Gel): a candidate dendrimer-microbicide for the prevention of HIV and HSV infection. Int J Nanomedicine 2007; 2:561-566. This review article summarizes the results of studies with VivaGel.
57. McCarthy TD, Karellas P, Henderson SA, et al. Dendrimers as drugs: discovery and preclinical and clinical development of dendrimer-based microbicides for HIV and STI prevention. Mol Pharm 2005; 2:312-318.
58. Brache V, Cohen JA, Cochon L, Alvarez F. Evaluating clinical safety of three vaginal applicators: a pilot study conducted in the Dominican Republic. Contraception 2006; 73:72-77.
59. Woolfson AD, Malcolm RK, Toner CF, et al. Potential use of vaginal rings for prevention of heterosexual transmission of HIV: a controlled-release strategy for HIV microbicides. Am J Drug Delivery 2006; 4:7-20.
60. Malcolm RK, Woolfson AD, Toner CF, et al. Long-term, controlled release of the HIV microbicide TMC120 from silicone elastomer vaginal rings. J Antimicrob Chemother 2005; 56:954-956.
61. Woolfson AD, Malcolm RK, Morrow RJ, et al. Intravaginal ring delivery of the reverse transcriptase inhibitor TMC 120 as an HIV microbicide. Int J Pharm 2006; 325:82-89.
62. th Conference on Retroviruses and Opportunistic Infections; 25-28 February 2007; Los Angeles. Alexandria: CROI; Abstract 1000.
63. th Conference on Retroviruses and Opportunistic Infections; 3-6 February 2008; Boston. Alexandria: CROI; Abstract #559b.
64. Han YA, Singh M, Saxena BB. Development of vaginal rings for sustained release of nonhormonal contraceptives and anti-HIV agents. Contraception 2007; 76:132-138. This papers reports on development and characterization of IVRs containing nonhormonal contraceptives or AZT.
65. Hoffmann C, Focke N, Franke G, et al. Comparative bioavailability of metronidazole formulations (Vagimid) after oral and vaginal administration. Int J Clin Pharmacol Ther 1995; 33:232-239.
66. Larsson B, Kjaeldgaard A. Combined vaginal and vulval treatment of vaginal candidiasis with econazole. Curr Ther Res Clin Exp 1980; 27:664-669.
67. Du LD, Ni JM, Meng QG, Shi YB. Preparation of actinomycin D vaginal bioadhesive tablet. Chinese Journal of New Drugs 2007; 16:387-390.
68. Joshi SN, Katti U, Godbole S, et al. Phase I safety study of Praneem polyherbal vaginal tablet use among HIV-uninfected women in Pune, India. Trans R Soc Trop Med Hyg 2005; 99:769-774.
69. Joglekar NS, Joshi SN, Navlakha SN, et al. Acceptability of Praneem polyherbal vaginal tablet among HIV-uninfected women & their male partners in Pune India - phase I study. Indian J Med Res 2006; 123:547-552.
70. Fernandez-Alba J, Valle-Gay A, Dibildox M, et al. Fenticonazole nitrate for treatment of vulvovaginitis: Efficacy, safety, and tolerability of 1-gram ovules, administered as ultra short 2-day regimen. J Chemother 2004; 16:179-186.
71. Baloǧlu E, Ozyazici M, Yaprak Hizarcioǧlu S, et al. Bioadhesive controlled release systems of ornidazole for vaginal delivery. Pharm Dev Technol 2006; 11:477-484.
72. El-Gindy GA, El-Sayed AM, Mohamed AA, et al. Mucoadhesive vaginal tablets of natamycin for vaginal candidiasis. Bulletin of Pharmaceutical Sciences 2003; 26 (Part 1):29-40.
73. Gursoy A, Bayhan A. Testing of drug release from bioadhesive vaginal tablets. Drug Dev Ind Pharm 1991; 17:2457-2475.
74. Mauck CK, Allen S, Baker JM, et al. An evaluation of the amount of nonoxynol- 9 remaining in the vagina up to 4 h after insertion of a vaginal contraceptive film (VCF) containing 70mg nonoxynol-9. Contraception 1997; 56:103-110.
75. Mauck CK, Baker JM, Barr SP, et al. A phase I comparative study of contraceptive vaginal films containing benzalkonium chloride and nonoxynol-9, Post-coital testing and colposcopy. Contraception 1997; 56:89-96.
76. Iizuka R, Kobayashi T, Kawakami S, et al. Clinical experience of vaginal contraceptive film containing the spermicide, polyoxyethylene nonylphenyl ether [in Japanese]. Nippon Funin Gakkai Zasshi 1980; 25:64-68.
77. Roddy RE, Zekeng L, Ryan KA, et al. A controlled trial of nonoxynol 9 film to reduce male-to-female transmission of sexually transmitted diseases. N Engl J Med 1998; 339:504-510.
78. Garg S, Vermani K, Garg A, et al. Development and characterization of bioadhesive vaginal films of sodium polystyrene sulfonate (PSS), a novel contraceptive antimicrobial agent. Pharm Res 2005; 22:584-595.
79. Neurath AR, Strick N, Li YY. Water dispersible microbicidal cellulose acetate phthalate film. BMC Infect Dis 2003; 3:27.
80. Yoo JW, Dharmala K, Lee CH. The physicodynamic properties of mucoadhesive polymeric films developed as female controlled drug delivery system. Int J Pharm 2006; 309:139-145.
81. Neurath AR, Strick N, Li YY, Debnath AK. Cellulose acetate phthalate, a common pharmaceutical excipients, inactivates HIV-1 and blocks the coreceptor binding site on the virus envelope glycoprotein gp120. BMC Infect Dis 2001; 1:17.
82. Mauck CK, Baker JM, Barr SP, et al. A phase I comparative study of three contraceptive vaginal films containing nonoxynol-9: Post coital testing and colposcopy. Contraception 1997; 56:97-102.
83. Hjartstam J, Hjertberg T. Swelling of pellets coated with a composite film containing ethyl cellulose and hydroxypropyl methylcellulose. Int J Pharm 1998; 161:23-28.
84. Garg S, Kandarapu R, Vermani K, et al. Development pharmaceutics of microbicide formulations. Part I: Preformulation considerations and challenges. AIDS Patient Care and STDs 2003; 17:17-32.
85. Vermani K, Garg S, Zaneveld LJ. Assemblies for in vitro measurement of bioadhesive strength and retention characteristics in simulated vaginal environment. Drug Dev Ind Pharm 2002; 28:1133-1146.
86. Pongjanyakul T, Puttipipatkachorn S. Alginate-magnesium aluminum silicate composite films: Effect of film thickness on physical characteristics and permeability. Int J Pharm 2008; 346:1-9.
87. Tabet SR, Surawicz C, Horton S, et al. Safety and toxicity of nonoxynol-9 gel as a rectal microbicide. Sex Transm Dis 1999; 26:564-571.
88. Phillips DM, Taylor CL, Zacharopoulous VR, Maquire RA. Nonoxynol-9 causes rapid exfoliation of sheets of rectal epithelium. Contraception 2000; 62:149-154.
89. Phillips DM, Sudol KM, Taylor CL, et al. Lubricants containing N-9 may enhance rectal transmission of HIV and other STIs. Contraception 2004; 70:107-110.
90. Patton DL, Cosgrove Sweeney YT, Rabe LK, Hillier SL. Rectal applications of nonoxynol-9 cause tissue disruption in a monkey model. Sex Transm Dis 2002; 29:581-587.
91. Anton PA. A phase I randomized, blinded, placebo-controlled safety and acceptability study of the UC-781 vaginal microbicide gel formulation applied rectally in HIV-1 seronegative adults [abstract]. In: Microbicides 2006; 23-26 April 1006; Cape Town. Washington, DC: Global Campaign for Microbicides; 2006.
92. Fuchs EJ, Lee LA, Torvenson MS, et al. Hyperosmolar sexual lubricant causes epithelial damage in the distal colon: Potential implication for HIV transmission. J Infect Dis 2007; 195:703-710. This paper established the importance of osmolarity of formulations intended for rectal administration. Hyperosmolar formulations cause greater tissue damage than iso-osmolar formulations, which may increase susceptibility to HIV infection.
93. Swarbrick J, Boylan JC, editors. Encyclopedia of pharmaceutical technology. Volume 13. New York: Marcel Dekker; 1996.
94. Mackay M, Phillips J, Hastewell J. Peptide drug delivery: Colonic and rectal absorption. Adv Drug Deliv Rev 1997; 28:253-273.
95. Remington JP, Beringer P. Remington: The science and practice of pharmacy. 21st edition Philadelphia: Lippincott Williams & Wilkins; 2006.
96. th ed Philadelphia: Lippincott Williams & Wilkins; 1999.
97. Kakoulides EP, Smart JD, Tsibouklis J. Azocross-linked poly(acrylic acid) for colonic delivery and adhesion specificity: In vitro degradation and preliminary ex vivo bioadhesion studies. J Control Release 1998; 54:95-109.
98. Smolensky MH, Peppas NA. Chronobiology, drug delivery, and chronotherapeutics. Adv Drug Deliv Rev 2007; 59:828-851.
99. 8th ed. Montvale: Thomson Healthcare; 2004.
100. Touitou E, Barry BW. Enhancement in Drug Delivery. Boca Raton, FL: CRC Press; 2006.
101. Jones RW, Waugh AE, Woodage TJ, et al. The pharmacokinetics and acceptability of benoxaprofen following rectal administration. J Rheumatol Suppl 1980; 6:20-26.
102. de Boer AG, Moolenaar F, de Leede LG, Breimer DD. Rectal drug administration: clinical pharmacokinetic considerations. Clin Pharmacokinet 1982; 7:285-311.
103. Teter CJ, Phan KL, Cameron OG, Guthrie SK. Relative rectal bioavailability of fluoxetine in normal volunteers. J Clin Psychopharmacol 2005; 25:74-78.
104. Miyazaki S, Suisha F, Kawakaski N, et al. Thermally reversible xyloglucan gels as vehicles for rectal drug delivery. J Control Release 1998; 56:75-83.
105. Park YJ, Yong CS, Kim HM, et al. Effect of solium chloride on the release, absorption and safety of diclofenac sodium delivered by polyoxamer gel. Int J Pharm 2003; 263:105-111.
106. Choi HG, Jung JH, Ryu JM, et al. Development of in-situ gelling and mucoadhesive acetaminophen liquid suppository. Int J Pharm 1998; 165:33-44.
107. Choi HG, Oh YK, Kim CK. In-situ gelling and mucoadhesive liquid suppository containing acetaminophen: Enhanced bioavailability. Int J Pharm 1998; 165:23-32.
108. Malchow H, Gertz B, CLAFOAM Study Group. A new mesalazine foam enema (Claversal Foam) compared with a standard liquid enema in patients with active distal ulcerative colitis. Aliment Pharmacol Ther 2002; 16:415-423.
109. Klotz U, Schwab M. Topical delivery of therapeutic agents in the treatment of inflammatory bowel disease. Adv Drug Deliv Rev 2005; 57:267-279.
110. Dash AK, Gong Z, Miller DW, et al. Development of a rectal nicotine delivery system for the treatment of ulcerative colitis. Int J Pharm 1999; 190:21-34.
111. Ingram JR, Rhodes J, Evans BK, et al. Comparative study of enema retention and preference in ulcerative colitis. Postgrad Med J 2005; 81:594-598.
112. Pokrotnieks J, Marlicz K, Paradowski L, et al. Efficacy and tolerability of mesalazine foam enema (Salofalk foam) for distal ulcerative colitis: A doubleblind, randomized, placebo-controlled study. Aliment Pharmacol Ther 2000; 14:1191-1198.
113. Gionchetti P, Ardizzone S, Benvenuti ME, et al. A new mesalazine gel enema in the treatment of left-sided ulcerative colitis: a randomized controlled multicentre trial. Aliment Pharmacol Ther 1999; 13:381-388.
114. Brouard A, Fontan JE, Masselin S, Terrier JL. Rectal administration of carbamazepine gel. Clin Pharm 1990; 9:13-14.
115. Fawaz F, Koffi A, Guyot M, Millet P. Comparative in vitro-in vivo study of two quinine rectal gel formulations. Int J Pharm 2004; 280:151-162.
116. Adikwu MU, Okafor JO. Evaluation of mucin as a release enhancer for rectal delivery of glibenclamide. Curr Drug Deliv 2006; 3:243-254.
117. El-Kamel A, El-Khatib M. Thermally reversible in situ gelling carbamazepine liquid suppository. Drug Deliv 2006; 13:143-148.
118. Paek SH, Xuan J, Choi HG, et al. Poloxamer 188 and propylene glycol-based rectal suppository enhances anticancer effect of 5- Fluorouracil in mice. Boil Pharm Bull 2006; 29:1060-1063.
119. Ofokansi KC, Adikwu MU, Okore VC. Preparation and evaluation of mucingelatin mucoadhesive microspheres for rectal delivery of ceftriaxone sodium. Drug Dev Ind Pharm 2007; 33:691-700. This paper describes a microsphere formulation technology relevant for topical delivery of microbicides.
120. Ryu JM, Chung SJ, Lee MH, et al. Increased bioavailability of propranolol in rats by retaining thermally gelling liquid suppositories in the rectum. J Control Release 1999; 59:163-172.
121. Khafagy el-S, Morishita M, Onuki Y, Takayama K. Current challenges in noninvasive insulin delivery systems: a comparative review. Adv Drug Deliv Rev 2007; 59:1521-1546.
122. Barichello JM, Morishita M, Takayama K, et al. Enhanced rectal absorption of insulin-loaded pluronic F-127 gels containing unsaturated fatty acids. Int J Pharm 1999; 183:125-132.
123. Uchida T, Toida Y, Sakakibara S, et al. Preparation and characterization of insulin-loaded acrylic hydrogels containing absorption enhancers. Chem Pharm Bull (Tokyo) 2001; 49:1261-1266.
124. Hardy E, Hebling EM, Sousa MH, et al. Delivery of microbicides to the vagina: difficulties reported with the use of three devices, adherence to use and preferences. Contraception 2007; 76:126-131. This article is the first to compare user preferences for microbicide delivery systems, including vaginal ring devices.
125. Elias C, Coggins C. Acceptability research on female-controlled barrier methods to prevent heterosexual transmission of HIV: Where have we been? Where are we going? J Women's Health Gend Based Med 2001; 10:163-173.
126. Steiner M, Spruyt A, Joanis C, et al. Acceptability of spermicidal film and foaming tablets among women in three countries. International Family Planning Perspectives 1995; 21:104-107.
127. Hardy E, Jiménex AL, de Pádua KS, Zaneveld LJ. Women's preferences for vaginal antimicrobial contraceptives. III. Choice of a formulation, applicator, and packaging. Contraception 1998; 58:251-255.
128. Hardy E, de Pádua KS, Jiménex AL, Zaneveld LJ. Women's preferences for vaginal antimicrobial contraceptives. I. Methodology. Contraception 1998; 58:233-238.
129. Hardy E, de Pádua KS, Jiménex AL, Zaneveld LJ. Women's preferences for vaginal antimicrobial contraceptives. II. Preferred characteristics according to women's age and socioeconomic status. Contraception 1998; 58:239-244.